Chaga

A 0 mg chaga extract with an identified beta-glucan form provides a stronger quality signal than an unspecified mushroom powder. That stronger dose or ingredient characterization makes it a more informative chaga option than the original, although the exact beta-glucan yield, species, extraction method, and source part are still not supplied.

The label identifies Inonotus obliquus sclerotium extract and supplies 900 mg, improving species and mushroom-part clarity. That stronger dose or ingredient characterization makes it a more informative chaga option than the original, although the extraction ratio and active-marker standardization remain unstated.

A substantial 1800 mg chaga extract with polysaccharide identification gives the formula useful dose and potency context. That stronger dose or ingredient characterization makes it a more informative chaga option than the original, although the precise polysaccharide yield, species, mushroom part, and extraction method remain unclear.

A clearly stated 400 mg chaga amount keeps the formula simple and easy to use. A lower serving cost improves routine value, although species, mushroom part, extraction method, and active-marker potency remain unclear.

A clearly stated 1000 mg chaga amount keeps the formula simple and easy to use. A lower serving cost improves routine value, although species, mushroom part, extraction method, and active-marker potency remain unclear.

A 0 mg chaga extract with an identified beta-glucan form provides a stronger quality signal than an unspecified mushroom powder. A lower serving cost improves routine value, although the chaga amount is modest, and 30 mg of zinc may be excessive for unmonitored long-term use.

A 0 mg chaga extract with an identified beta-glucan form provides a stronger quality signal than an unspecified mushroom powder. Its formulation quality and serving economics provide a useful value balance, although the exact beta-glucan yield, species, extraction method, and source part are still not supplied.

Chaga, cordyceps, and reishi provide broader mushroom coverage than a single-ingredient formula. Its formulation quality and serving economics provide a useful value balance, although species, mushroom parts, extraction details, and active-marker levels are missing, and reishi may add bleeding concern with anticoagulant or antiplatelet medicines.

Chaga joins maitake, gymnema, cinnamon, and bilberry in a blend aimed more at glucose support than focused mushroom use. Its formulation quality and serving economics provide a useful value balance, although gymnema and cinnamon may add to glucose-lowering medicines, while mushroom quality markers are not stated.